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Abstract
Chikungunya fever (CF) is an arboviral disease in worldwide expansion due to the plasti‐
city of its pathogen and vector. Chikungunya virus (CHIKV), a positive-sense, single-
stranded RNA alphavirus, is transmitted by Aedes (Stegomyia) aegypti and Aedes albopictus
mosquitoes, two hegemonic anthropophilic day-biting mosquitoes capable of colonizing
very different environments. This expert review discusses the molecular epidemiology,
pathophysiology, clinical features, diagnosis, management, and prevention of CF during
pregnancy, infancy, and childhood. Specifically, it will focus not only on the issue and
challenges of perinatal mother-to-child transmission of CHIKV, its pathogenesis, and ef‐
fects on neurodevelopment, but also on CHIKV-associated central nervous system dis‐
ease in children, two previously ill-characterized features of the infection.
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1. Introduction
Chikungunya fever (CF) is an arthropod-borne viral disease caused by the chikungunya virus
(CHIKV) [1]. First described during an outbreak of dengue-like illness in the Newala district
of the southern province of Tanganiyika (current Tanzania) in 1952–1953, the virus derives its
name from the Makonde language and means “to become contorted” or “that which bends
up” [2, 3]. These descriptors refer to the hallmark of the disease observed in adults, namely,
severe incapacitating arthralgia, which was characterized as “frightening” in the seminal
description of Robinson [4], as they lead to an inability to stand or walk [5]. In the majority of
adult patients with CF, painful arthritis can continue for months and even years, yielding a
significant persistent disease burden in affected populations [6–9]. CF is usually not life-
threatening, although atypical and severe forms can occur during large-scale epidemics and
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a slight increase of mortality has accompanied the peak of the outbreak in La Réunion island
[10–15]. Indeed, CHIKV-associated mortality is considered rare (~1‰ infections), but occurs
primarily among the elderly, as evidenced in La Réunion, India, or in Puerto Rico [15–17].
Genome-scale phylogenetic analyses of CHIKV suggest that the virus originated from Africa
and was subsequently introduced from Africa into Asia [18]. Phylogenetically, CHIKV has
evolved into three distinct clades across the past five centuries: Asian, East Central South
African (ECSA), and West African lineages.
In its natural cycle, CHIKV is transmitted by the bite of female arboreal Aedes (Stegomyia)
mosquitoes. The peridomestic Ae. aegypti, the well-known vector of yellow fever and dengue,
was identified as the primary vector of CHIKV during its inaugural outbreaks, both in Africa
[2] and Asia [19]. It is only during the last decade that Ae. albopticus (also known as the Asian
tiger mosquito) has been recognized as a new propagating vector of CHIKV [20]. Originally
native to Southeast Asia, Ae. albopticus has adapted successfully to cooler climates and spread
worldwide [21]. Alongside the broadening geographic distribution of this new hegemonic
vector, genetic adaptation through mutations in the envelope glycoproteins E1 and E2 has led
to increased infectivity and dissemination of CHIKV in Ae. albopictus [22]. Moreover, rapidly
increasing international travel exposures has contributed to the global expansion of CF. Over
the last decade, ECSA CHIKV has been responsible for most of the recorded cases worldwide;
however, in late 2013 somewhat surprisingly Asian CHIKV emerged in the Caribbean island
of Saint-Martin [23] and further spread to the neighboring islands and to the Americas, causing
over 1.6 million cases by November 13, 2015 [24].
In addition to horizontal mosquito-borne transmission, CHIKV can also be transmitted
vertically, and mother-to-child transmission of CHIKV infection often leads to severe neonatal
disease, mostly encephalitis, that may cause lifelong disabilities [25]. This expert review will
discuss the molecular epidemiology, pathophysiology, clinical features, diagnosis, manage‐
ment, and prevention of CF in the pregnant woman and in children, with a particular focus
on the issue and challenges of congenital infection.
2. Molecular epidemiology
2.1. The chikungunya virus
CHIKV is a positive-sense, single-stranded RNA virus (genus Alphavirus, family Togaviri‐
dae), whose genome encodes at the 5′ extremity four nonstructural proteins (nsP1, nsP2, nsP3,
and nsP4 responsible for negative-strand RNA synthesis, helicase and protease activity, RNA-
dependent RNA polymerase activity, respectively) and at the 3′ extremity three envelope
glycoproteins (E1, responsible for membrane fusion; E2, responsible for receptor binding and
virulence (E1 and E2 carrying the main epitopes); E3, which serves as a clade-specific signal
sequence for translocation of the glycoprotein complex in the endoplasmic reticulum) [26]. The
native monomeric capsid is of ∼40 nm diameter and the mature enveloped virion of ∼70 nm,
with a genome weighing ∼11.8 kB. In recent years, the ECSA clade has selected the A226V
substitution for better fitness to Ae. albopictus [27].
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2.2. Chikungunya virus life cycle and modes of transmission
CHIKV is endemic in Africa where it circulates in sylvatic/enzootic cycle between arboreal
mosquitoes (Ae. furcifer, Ae. taylori, Ae. africanus, and Ae. luteocephalus) and nonhuman primates
and bats as reservoir hosts. Birds and other mammals have been found infected, but serve as
occasional hosts without amplification of the virus [28]. In this context, the transmission
depends on few mosquitoes and is usually clustered to sporadic cases [29].
In epidemic settings, the virus is transmitted by Ae. albopictus or Ae. aegypti, two day-biting
anthropophilic vectors whose peak activity occurs early in the morning or in the evening,
around or within human dwellings [20]. During the blood meal, Aedes mosquitoes acquire the
virus from an infected person. In the subsequent extrinsic phase, the virus multiplies in the
gut and migrates to the salivary glands (≥2 days depending on temperature) [30]. Further blood
meals then transmit the virus to other individuals bitten (~4–5 feeds are needed to complete a
successful blood meal for oviposition). Aedes spp. mosquitoes remain infectious throughout
their whole life (30–45 days). Transmission between nonimmune human hosts is often massive
and both sustained by densities of host and vector populations, very high titer viremias in
humans, as well as by lack of protective host behaviors [29].
3. Pathophysiology
The onset of CF coincides with viremia (median duration: 5 days; range: 2–12 days). The
mechanisms underlying acute CHIKV infection are still imperfectly understood [1]. Based on
several animal models and meta-analysis of human immune signatures, once introduced into
the dermis, it is believed that CHIKV disseminates in blood circulation causing a Th1-cytokine
storm [31, 32]. CHIKV replicates in the liver hosted by endothelial and Küpffer cells, before
reaching joint fibroblasts, muscle satellite, and skin epithelial cells, causing arthralgia, myalgia,
and rash. Indeed, elective targeted sites where symptoms focus are typically infected, espe‐
cially joint capsules, skeletal muscles, myotendinous insertions, and epidermis [1].
The intensity of the acute infection correlates with the CHIKV viral load [1]. The ability of
CHIKV to disseminate through the body to the target organs is inversely correlated to the
height of the host type-1 interferon (IFN) response. There is evidence that this CHIKV-specific
innate immune response depends on the age and the maturity of the human host [33]. This
can be shown in vulnerable persons by the breaking of two natural protective barriers, the
blood brain barrier (BBB) and the skin barrier. Thus, infants and individuals >65 years of age
are likely to exhibit severe or atypical localizations, including CHIKV-associated central
nervous system (CNS) disease and severe bullous skin lesions. For example, the incidence of
CHIKV-associated encephalitis is best described by an asymmetric U-shaped parabolic curve
with the highest incidence occurring in infants below 6 months of age, the nadir being reached
in young children (1–4 years of age), and a rise in seniors (≥65 years of age) to a figure five-
fold lower than in infants [34]. Furthermore, skin blistering (rupture of bullous lesions) is
almost exclusively observed in infants below 6 months of age [35].
B cells and neutralizing antibodies (abs) are critical for CHIKV clearance. Targeted epitopes
for anti-CHIKV abs are located at C terminus of the E2 glycoprotein [36]. The contribution of
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lymphoid (CD4 and CD8) and other cell types responsible for the adaptive immunity could be
critical in residual arthralgia. Their immaturity may explain the rarity of chronic arthralgia
before the age of 3 years. The role of myeloid cells is less clear in the acute and chronic stage
of human CHIKV infection. At the acute stage, blood monocytes may be able to disseminate
the virus toward the target tissues [37]. At the chronic stage, myeloid cells may be involved in
the clearance of infected cell debris but whether CHIKV replication, lack of virus antigen
clearance, or both contribute to rheumatism deserves further studies.
The long-term persistence of CHIKV in tissue macrophages (aka “host sanctuaries”) as main
driver for chronic inflammation has been postulated from a single clinical observation [38]. It
is supported by the data from several animal models (i.e., “for example, see [31]”).
4. Clinical features
4.1. Chikungunya fever during pregnancy
Pregnancy, a situation physiologically oriented toward a Th2-lymhocyte shift [39], has not
been associated as a condition precipitating severe forms of infection in CF [40].
The consequences for the mother and the fetus of a CHIKV infection acquired during preg‐
nancy have been investigated extensively on La Réunion island, both in the Groupe Hospitalier
Sud-Reunion cohort study [41, 42], in the CHIMERE (“Chikungunya Mère-Enfant”) cohort
study [43], and in the 2004–2006 Family Allowance Office (41,665 deliveries) and Mother and
Child Welfare (42,259 neonates) records [44]. To date, there is no reliable epidemiological data
linking CHIKV exposure in the first trimester of gestation to an increased risk for miscarriage,
nor to any type of congenital malformation [43, 44].
In the second trimester, CHIKV infection has been associated with only three cases of ante‐
partum fetal deaths without clear evidence for the mechanism [45]. The CHIKV crossing of
the placenta may be accidental and the timing of the infections (12 weeks + 4 days, 15 weeks,
and 15 weeks + 5 days) coincides in the woman with the period of deep trophoblast invasion.
We hypothesize Toll-like receptor (TLR) 3 expression and Th1 cytokines associated with
CHIKV infection could have disturbed the spiral arteries remodeling, characteristic of this
particular period. Our hypothesis is supported by the involvement of TLR3 in both the
susceptibility to CHIKV infection and the impairment of vascular remodeling or fetal losses,
as demonstrated in mouse models [46, 47].
In the third trimester, although 14 cases of stillborn fetuses have been reported associated with
CF in pregnant women cohorts [42, 43], none was positive for CHIKV, which supports the
nonpermissiveness of the human syncytiotrophoblast to CHIKV, as suggested by data from
the IFN-α/βR–/– mouse model and the absence of infection of BeWo cell line [33]. These findings
are strengthened by the data retrieved from French population-based records [44]. The
contribution of subclinical premature placental abruption has been proposed to support the
exceptional cases of prepartum CHIKV infection in preterm neonates [48].
Importantly, CHIKV can be transmitted vertically with a probability ~50%, when the parturi‐
ent woman has a high viral load during the early stage of labor [41–43]. Fetal heart rate
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decelerations and meconium-stained amniotic fluid are common during labor [42, 49]. Neither
postponing delivery nor cesarean has been shown to be protective. In this context, the alleged
mechanism to explain the transmission to the neonate is the breakdown of the syncytiotro‐
phoblast due to uterine contractions (aka the “placental breeches” hypothesis) [42] while
placental microtransfusion has not been ruled out by a proper scientific investigation.
There is no increased risk to the pregnant mother for hypertensive disorders, gestational
diabetes mellitus, or intrauterine growth restriction associated with maternal CF [43, 44, 50].
The relationships between average fetal birthweight, small-for-gestational age, and the timing
of maternal CF during pregnancy are displayed in Figure 1.
(a) (b) 
(c) (d) 
Liveborn neonates were matched on birth gestational age and further compared according to the timing of maternal chikungunya
fever during pregnancy. There was no statistical difference between exposed (purple) and unexposed (green) neonates in terms of
small-for-gestational age incidence and the only observed difference was a non-clinically relevant lower mean birthweight in neo‐
nates exposed in the second trimester of pregnancy (*).
Figure 1. Average fetal birthweight, small-for-gestational age and the timing of maternal CF during pregnancy, Reun‐
ion island 2006 (i.e., “for details see [50].”).
Contrary to dengue [51, 52], there is also no increased risk for obstetric hemorrhage (placental
abruption), preterm birth or low birthweight [43, 44, 50].
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4.2. Chikungunya fever in the neonate (“congenital chikungunya”)
Perinatal mother-to-child CHIKV infection was first reported during La Réunion island
outbreak in year 2005 [53]. It has been investigated extensively on the island using both a
retrospective regional case series [54] and two prospective hospital-based cohort studies, one
on a local basis, the GHSR child cohort study [42], and the other on a regional basis, the
“CHIMERE child” cohort study [55, 56].
Children who are prenatally infected with CHIKV are born with very low or even undetectable
viremia, which makes the hypothesis of placental microtransfusion unlikely as the expected
neonatal viremia would parallel the one of the mother. On average, it takes 4–5 days (range:
3–7 days) for the viral load of CHIKV transmitted at birth to reach a level significant enough
to cause clinical disease. Neonatal CHIKV infection almost invariably presents with fever, pain,
and suckling difficulties often requiring enteral or parenteral nutrition [42]. Other common
symptoms include limb edema, petechiae, and a skin rash such as maculopapular rash and
intertriginous aphthous-like ulcers [25]. Further clinical features of neonatal CHIKV infection,
although relatively infrequent in this age group, are cyanosis (slate coloration) and hyperpig‐
mentation of the skin [35, 50, 55, 57–61]. Their topography includes centro-facial area (nose,
lips), trunk, abdomen, extremities, and knuckles. Hyperpigmentation may persist for several
weeks to months. Vesiculobullous skin lesions are exceptional [62]. Thrombocytopenia,
lymphopenia, and mild to moderate increases of serum aspartate aminotransferase (AST or
SGOT) are frequent observations [42, 54, 57–61].
Life-threatening complications occur in half of the neonates and display two main clinical
pictures: CHIKV-associated CNS disease (formerly reported as encephalopathy) that in fact
consists of an encephalitis [34] and a multiple organ dysfunction (MOD) syndrome that
combines a circulatory collapse (hypovolemia and hyperkinetic profile on echocardiography),
lethargy, hemorrhages (disseminated intravascular coagulation), uremia, and cytolysis [59].
These severe manifestations require intensive care support including mechanical ventilation
(for airway protection or neurosedation) in a quarter of neonates, vasoactive amines, and
platelet and red blood cell transfusions. Risk factors for severe disease are immaturity and low
birthweight. Indicators for severity include a reduced core to skin temperature, low prothrom‐
bin rate, and low platelet count [42].
The most characteristic magnetic resonance imaging (MRI) findings of the early acute stage
(day 7), subacute stage (day 30), and chronic stage (day 120) of CHIKV-associated encephalitis
are presented in Figure 2.
Changes in the course of cerebral edema and the passage from the cytotoxic to the vasogenic
phase occur around day 10 of onset of neurologic symptoms and may be monitored by
transfontanellar ultrasonography using velocimetry for measuring the blood flow in the
anterior cerebral artery trunks (pericallosal and calloso-marginal arteries). Other neuroradio‐
logic features include scattered supratentorial parenchymal lesions such as basal ganglia and
subcortical area bleeding, but also the possibility of cerebellar hematoma, as a reversible
consequence of DIC syndrome [42, 55, 60].
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Transient coronary arteries dilatation was reported for six neonates [55]. Cardiologic involve‐
ment in this context is evocative of myocardiopathy or myocarditis, it includes left ventricular
hypertrophy (sometimes complicated by left ventricular dysfunction or septal dyskinesia) and
pericardial effusion [55, 61].
To date, only few CHIKV-associated deaths in neonates have been reported [55, 61, 62]. For
the neonates without neurological involvement, recovery was observed in 1–3 weeks without
sequelae; however, future long-term studies will shed more light on the presence of subtle
morbidities related to CF in these infants [63]. The neurodevelopmental outcome associated
with perinatal mother-to-child CHIKV infection will be discussed in Section 4.5.
To investigate the potential for serological evidence of congenital infection in apparently
healthy neonates born to women infected with CHIKV during pregnancy, we monitored the
kinetics of transplacental CHIKV-specific IgG abs within the CHIMERE cohort study [55].
At day 7 of life, diffusion-weighted imaging (DWI) reveals scattered hyper-intensity signals of the white matter (WM), as marked
in the frontal lobe (red star) or in the posterior arm of the corpus callosum (red arrows) evocative of cytotoxic edema (A), apparent
diffusion coefficient (ADC) reveals low-output areas (blue) of restriction evocative of parenchymal ischemia (B). At day 30, DWI
reveals scattered hypo-intensity signals of the WM in the same areas evocative of vasogenic edema (C), ADC reveals high-output
areas of reperfusion (red) evocative of blood brain barrier leakage (D). At day 120, T2-weighted (T2W) and T1-weighted imaging
(T1-W1) reveal a scattered scalloped appearance of the WM (blue star), a dilatation of the interhemispheric sulcus (double blue
arrow) indicative of WM mass reduction (E,F), focused in the frontal (blue oval) lobe (G), monovoxel spectroscopy reveals a lower
N-acetyl aspartate peak signal (red arrow) in the left posterior parietal lobe (P2) evocative of axonal loss (H).
Figure 2. Typical course of cerebral edema over a 4-month period in a neonate with CHIKV-associated CNS disease
previously defined as “severe encephalopathy” [42], reclassified as CHIKV-associated encephalitis [34], Reunion is‐
land, 2006.
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There was no evidence of asymptomatic congenital CHIKV infection as the 590 participating
neonates were all negative for CHIKV-specific IgM at birth and the 368 children with CHIKV-
specific IgG present at birth had undetectable levels of CHIKV-specific IgG by a mean of 7.7
months (range: 1–24 months). Seroreversion time (i.e., the time needed to clear transplacental
IgG from infant blood or the duration until IgG is undetectable) was inversely correlated to
the timing of exposure during pregnancy. Preterm-born infants seroversed earlier. Full-term
small-for-gestational age seroreversed earlier than full-term normal-for-gestational age
neonates (Figure 3).
These Kaplan-Meier curves illustrate the bodysize-dependent transfer of transplacental CHIKV-specific IgG antibodies: the seropo‐
sitivity rate is lower in the first post-natal year and the seroreversion time is shorter in full-term small-for-gestational age neonates
compared to full-term normal-for gestational-age counterparts.
Figure 3. Seroreversion time of transplacental CHIKV-specific IgG antibodies in full-term normal-for-gestational age
(NGA) and full-term small-for-gestational age (SGA) infants, CHIMERE study, Reunion island 2008 (i.e., “for more de‐
tails, see [55].”).
These data corroborate a time-dependent and size-dependent placental transfer of maternal
IgG: the longer the period of exposure to maternal IgG and the larger the placenta, the higher
the load of the IgG transferred to the fetus, and the longer the seroreversion time and theo‐
retically the child’s individual protection. These issues may be helpful for maternal or postnatal
immunization, should a vaccine become available.
4.3. Chikungunya fever in infants
To the best of our knowledge, only a few case series described the clinical manifestations of
postnatally acquired CF in infants [64–71].
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The largest pediatric series published to date, from Kerala, India, including 357 suspected and
35 confirmed cases, reported 140 infants of whom 57% had circulatory collapse and 80% febrile
seizures [66]. In another series from Kerala including 56 infants with confirmed CHIKV
infection, the main symptoms were fever (100%), skin rash (100%), acrocyanosis (75%),
diarrhea (41%), atypical febrile seizures (39%), irritability (26%), lethargy/poor feeding (21%),
and limb edema (11%) [67]. Note that the authors have dissected the sequence of skin involve‐
ment: abrupt onset of generalized erythematous rash (day 0 to 2 of fever), maculopapular rash
(day 2 to 4), vesiculobullous lesions (day 3 to 6), peeling (day 6 to 10), and hypo- or hyperpig‐
mentation (>day 10).
These data have been confirmed in La Réunion island where half of the infants below 6 months
of age exhibited vesiculobullous skin lesions [68, 88]. Importantly, besides the susceptibility
for neurological complications (six-fold higher incidence rate of encephalitis) [34], these
vesiculobullous skin lesions have emerged as the most characteristic finding of CHIKV
infection in this age group [25, 70, 72, 73]. Severe perianal involvement is a characteristic
localization [67]. Blisters sometimes cover more than 30% of the body surface, and therefore
management resembles that of severe burn patients [70]. Mucosal lesions have not been
reported to date. Histopathologic examination of the blisters occurring in the course of CHIKV
infection reveals intraepidermal cleavage (splitting beneath and within the stratum granulo‐
sum) with CHIKV-specific IgM deposits onto the basal layer or the dermal capillaries. On
follow-up, long-term repigmentation is usually observed, sometimes with skin sequelae
including discrete peripheral hyperpigmentation and keloid scars.
4.4. Chikungunya fever in children
As for children in the first year of life, fever is the main symptom in older children and is
usually high grade (102/39–104/40 °F/°C) of sudden onset (<24 hours) and single-spiked [25,
64, 65, 74]. Febrile seizures are common but variably present in 14-80% of the cases. They also
occur beyond the typical age range of 6 months to 6 years [25, 64, 69, 73, 74]. Other common
symptoms accompanying fever include musculoskeletal pain (30–50%), skin rash (>30%),
headache (15%), and photophobia (<10%) [25, 68, 74].
In contrast to adults, arthritis is uncommon in children [25, 74]: 9 of 22 (40%) children reported
arthralgia and 6 of 22 (27%) reported arthritis during the Vellore epidemic, Tamil Nadu, India
[64]. Residual arthralgia or arthritis is also far less frequent than reported in adults. In the
TELECHIK population-based cohort study [75], they were reported in ∼6% of children, two
years after acute infection. Unfortunately, these data cannot be retrieved from observational
studies or case series, either by lack of follow-up or inability to extract the pediatric data.
The most commonly reported skin manifestations were maculopapular exanthema (morbilli‐
form or generalized) [35, 74, 76], pigmentary changes (diffuse or macular) [77], and intertrigi‐
nous aphthous-like ulcers [75]. Itching is common. Vesiculobullous skin lesions are possible
but rare beyond 1 year of age [77].
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Hemorrhagic manifestations including epistaxis, gum, subconjunctival bleeding, and purpura
are observed in ∼10% of pediatric cases [25]. They are less severe than in children dengue
fever.
CHIKV-associated sepsis is less common in toddlers (1–2 years) than in infants (<1 year) and
exceptional in children (3–18 years) [64, 76, 78]. In infants, circulatory collapse should prompt
cardiologic investigation, including echocardiography as cases of acute cardiac failure have
been described during CF [79–81] and myocarditis demonstrated in a young adult [82].
Neurological symptoms have been notified in the acute phase of CF in 25–30% of hospitalized
children on the island of La Réunion [25, 68, 69, 83] but were also observed in India [64–66, 74,
84–86]. Their burden will be described in the next section.
4.5. Chikungunya-virus-associated central nervous system (CNS) disease
CHIKV has long been suspected to be a neurovirulent pathogen [86]. Thus, the seminal
publications of CHIKV-associated neuropathology came from India [64] and Cambodia [87].
Among the neurological manifestations complicating CHIKV infection, three distinct clinical
patterns can be seen: (i) CHIKV-associated CNS disease, namely encephalopathy of chikun‐
gunya origin and CHIKV-associated encephalitis [34, 42]; (ii) CHIKV-associated peripheral
nerve disease, including myeloradiculitis and polyradiculoneuritis, and (iii) a putative non-
specific neurobiologic disease (e.g., lethargy, irritability, altered mental status, mild cognitive
disorders, fatigue, etc.) not entirely satisfying the two aforementioned conditions and pre‐
sumably resulting from penetration of proinflammatory cytokines through the BBB. Although
nonspecific neurological symptoms and CHIKV-associated CNS disease are deemed to be
common in children, CHIKV-associated peripheral nerve disease (Guillain-Barré syndrome
often referred as acute flaccid paralysis) seems exceptional [74, 87].
Indeed, hospital-based series have identified headaches, seizures, altered mental status such
as confusion or delirium, and neck stiffness as common signs of CNS involvement [83, 84].
Status epilepticus, complex seizures, and encephalitis are being reported as the most serious
complications of CNS involvement [25]. Importantly, while the overall burden of neurological
manifestations seems to increase with age, the incidence of CHIKV-associated CNS disease
peaks in children less than 5 years [34]. This is also highlighted by the fact that fatigue or mild
neuropsychiatric symptoms (attention difficulties, sleep, memory, or mood disorders) were
reported for 84% of school-age children participating to the TELECHIK cohort study, on
average 2 years after acute infection [7].
We propose to represent the burden of neurological manifestations of CF in children using a
pyramid (Figure 4), as done classically in public health for vector-borne zoonosis [88].
Little is known on the long-term outcome of CHIKV-associated CNS disease [34]. For example,
the neurodevelopmental outcome of perinatal mother-to-child CHIKV infection in the
CHIMERE cohort study revealed that 51% of infected neonates had a global neurodevelop‐
mental delay (GND; Brunet-Lézine development quotient ≤ 85) at the age of 2 years [56]. The
skill areas affected were coordination and language (57%), sociability (36%), and movement/
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posture (27%). Importantly, CHIKV infection was an independent predictor for GND after
adjustment for maternal social status, infant’s weight-for-gestational age, and head circum‐
ference, but also when controlling for preterm birth and breastfeeding. Five of the 12 neonates
with CHIKV-associated “encephalopathy” developed a microcephaly of whom 4 matched the
definition of cerebral palsy. Note that GND was observed in 38% of the CHIKV-perinatally
infected neonates in which CNS disease was not previously suspected.
5. Diagnosis
5.1. Differential diagnosis
Even though viral diseases are a major public health concern, they are not given due recogni‐
tion as a cause of fever in febrile children in resource limited settings [89]. The differential
This pyramid presents the incidence data and proportions of clinical forms according to epidemiological standards for reporting the
community burden of infectious diseases.
Figure 4. Burden of CHIKV-associated CNS disease in children, Southern Reunion island, 2009 (i.e., “source SERO‐
CHIK, TELECHIK and ENCEPHALCHIK studies, see [11, 7, 34].”).
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diagnosis of a febrile child or pregnant woman with recent travel to or residency in tropical
areas affected by CHIKV is broad and should include malaria, dengue, influenza, hepatitis,
typhoid fever, leptospirosis, and rickettsial infections [25]. In addition, in areas, where these
pathogens are present, infections with other alphaviruses, flaviviruses, filoviruses, and
bunyaviruses should be considered. In infants, staphylococcal scalded skin syndrome [70] and
Kawasaki syndrome [90] should additionally be considered and excluded as the two diagnoses
require a specific treatment. Among those listed, dengue is the infection most capable of
mimicking CF [25]. Clinical signs including fever pattern, arthralgia, and rash cannot reliably
be used to distinguish dengue fever from CF [91]. However, rash appears earlier in the course
of CF than it does in dengue fever, and dengue fever is more likely to be associated with
bleeding. Pregnancy-induced hypertension, placental abruption, and preterm labor are more
common in pregnant woman with dengue than with CF [51, 52].
5.2. Virological methods
After onset of CF, the viral load can rapidly reach up to 108 genome copies per ml of blood
(even a maximum of 2.5 × 108 cps/ml in neonates) [1, 42]. During the first 5 days of infection,
the CHIKV genome can be detected in the blood by reverse transcription polymerase chain
reaction (RT-PCR). The virus may also be detected in the cerebrospinal fluid of children with
CHIKV-associated CNS disease [25] and in blisters of infants with bullous skin lesions [62].
RT-PCR can be designed in multiplex assays to detect other arboviruses [92], which can be
very useful for triage of patients [1]. Techniques have continuously improved over the years
to allow diagnosis in 2 hours with a minimum cutoff for detecting circulating viremia as low
as 40 genome copies/ml using a 5 ml blood sample in TaqMan real-time PCR [93].
5.3. Serological methods
CHIKV-specific IgM and IgG can be detected in serum by enzyme-like-immunosorbent assay
(ELISA) immunocapture. CHIKV-specific IgM are detectable from 3 to 8 days after onset of
infection (p.o.i.) and may persist for several months to up to 2 years. CHIKV-specific IgG are
detectable from 4 to 10 days p.o.i. and may persist for years [1] and potentially lifelong.
Although, improvement has diminished the possibility of cross-reactivity of IgG with other
viruses of the Semliki antigenic serocomplex, it may still be useful to ensure a reliable diagnosis
of CHIKV infection by using IgG seroconversion (increase by a factor ≥4). In areas where
CHIKV and other closely related alphaviruses coexist, plaque reduction neutralization testing
becomes a necessary adjunct to confirm CHIKV infection [94].
5.4. Diagnostic testing depends on timing of illness onset
The molecular assays (TaqMan real-time PCR, RT-LAMP assay, and reverse transcription
PCR) are more sensitive in the early stage of CF (2–5 days p.o.i.) when CHIKV-specific IgM
are not yet detectable. In the later stages of CF (>5 days p.o.i.), CHIKV-specific IgM is more
sensitive than PCR. Experts recommend that ELISA IgM be used as an initial screening test
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There is no specific treatment for CF. CF in pregnant women should be treated with antipy‐
retics and analgesics to prevent miscarriage, fetal demise, and limit the harmful consequences
of fever, as well as this new competing risk for the neurodevelopmental outcome of preterm
neonates.
6.2. Children
As in pregnant women, there is no specific treatment for CF. Management is symptomatic and
focuses on adequate hydration, antipyretics, and analgesics (paracetamol/acetaminophen 60–
80 mg/kg/day) [25]. Experts recommend withholding salicylates, steroidal, and nonsteroidal
anti-inflammatory drugs (NSAIDs), as they may facilitate bleeding manifestations [73]. In La
Réunion island, ibuprofen had been thought to precipitate infant blistering but the association
was not statistically significant [96].
There are no antivirals that have been licensed to treat CF. Ribavirin and IFN-α have in vitro
an antiviral activity against CHIKV [97], the first being able to alleviate chronic arthralgia and
swelling [1]; however, neither one is recommended for use due to risk for side effects and nor
the other has been tested in children. It is hoped that in the future, safe and effective antivirals
will be able to offer specific CHIKV therapy.
Although persistent joint pain may be challenging to manage, NSAIDs together with cortico‐
steroids or methotrexate successfully have been used in adults [25].
Passive immunotherapy has proven efficacious in the cure of CHIKV infections in animal
models [98] and is currently being tested in neonates born to viremic mothers (i.e., “see
ClinicalTrials.gov number NCT02230163”) in French West Indies and French Guiana [1].
7. Prevention
7.1. Vaccination
By the end of year 2015, several promising vaccine candidates have reached late preclinical or
phase-1 testing and two have been scheduled for phase-2 trials [99]. The licensure of vaccines
will be challenging because of difficulties conducting affordable efficacy trials and predicting
future markets [1].
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7.2. Control of the vector
Preventive measures include community mobilization for eradication of breeding sites of Ae.
mosquitoes [100], which primarily dwell in natural and artificial water-filled container
habitats. During epidemics, peridomestic spraying of insecticides by residents and space
spraying by vector controls teams are key for reducing adult mosquito populations.
7.3. Individual protection against mosquito bites
Appropriate clothing (long clothes for gardening and evening walks) may minimize skin
exposure. Insect repellents containing DEET (N,N-diethyl-3-methylbenzamide), IR3535 (3-[N-
acetyl-N-butyl]-aminopropionic acid ethyl ester), or picaridin (1-piperidinecarboxylic acid
and 2-(2-hydroxyethyl)-1-methylpropylester) are effective [101]. DEET is safe for use in
pregnancy, though it is known to cross the placenta, and can be used in children of 3 months
of age and older [102]. Its putative neurotoxicity remains controversial [103]. In addition,
insecticide-treated nets are important for pregnant women, infants, and children who take
daytime naps. Indeed, rest under treated nets for acute patients should be considered as a pillar
of community protection and in the hospital setting during the period of viremia for at least 2
weeks. The effectiveness of both types of mechanical preventive measures has not been
assessed.
8. Conclusions and perspectives
CF is a tropical arthropod-borne virus infection whose geographical distribution has grown
steadily over the last decade as a result of global warming and globalization of transports.
CHIKV can also be transmitted vertically from mother-to-child during the perinatal period
when the parturient woman is highly viremic during labor. In the pediatric population, severe
forms of CF may occur, and the CNS is particularly affected with encephalitis as the major
syndrome of CHIKV-associated CNS disease. At pediatric ages, neonates and small infants
below 6 months of age have the highest risk for case fatality and lifelong disabilities.
Several knowledge gaps remain for CF in both pregnant women and children including: (i)
the effectiveness of postponing delivery and caesarian section; (ii) the genotype-specific
virulence of CHIKV and its ability to cause perinatal mother-to-child infection, CNS infection,
or other life-threatening complications; and (iii) are there possible interactions between CHIKV
and other circulating arboviruses in Aedes mosquito vectors susceptible to explain the rise of
arbovirus-related neurological disease? This question is critical both for CHIKV and Zika virus,
a conqueror flavivirus which has supplanted CHIKV wherever it has tried to establish in recent
years; (iv) the subtle long-term morbidities that CF may cause in children. The absence of
autopsy data with reliable histopathological findings (immunochemistry staining) prevents
understanding of the human CNS neuropathology.
Benchmarking of observational studies, meta-analysis of individual patient data, and well-
designed clinical trials should be of paramount importance to address these knowledge gaps.
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Future antivirals and vaccines may alleviate some of the disease burden, but for now vector
control and human personal protection are the only means of CF prevention.
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